Posted by freedom2001 on November 3, 2002, at 8:01:17
(R)-flextime ...The (R) -isomer of Eli Lilly's PROZAC(r) has the Potential to offer greater flexibility in treating depression compared to currently marketed antidepressants.
The unique pharmacology of (R)-fluoxetine offers the potential for more rapid onset of relief, greater efficacy for treatment of depression, and fewer side effects such as sexual dysfunction. (R)-Fluoxetine also offers the potential for treatment of additional indications, including anxiety. Improvements in its pharmacokinetic profile should allow for shorter washout and reduced drug- drug interaction. Eli Lilly has independently initiated large- scale efficacy studies with (R) - fluoxetine.In December 1998, Sepracor announced a proposed license agreement with Lilly relating to development and commercialization of (R)-fluoxetine. Under the terms of the agreement, Lilly shall have the worldwide exclusive right to develop and market products containing (R)-fluoxetine. Lilly will be responsible for all subsequent developmental work on (R)-fluoxetine, regulatory submissions, product manufacturing, marketing, and sales. Upon the effective date of the agreement, Sepracor is entitled to receive a milestone payment and license fee totaling $20 million. Sepracor also may receive up to $70 million in milestone payments based on the progression of (R)-fluoxetine through development. In addition, Sepracor is entitled to royalties on (R)-fluoxetine worldwide sales beginning upon first commercial sale. This license agreement is subject to approval by the Federal Trade Commission. PROZAC(r) (racemic fluoxetine) marketed by Eli Lilly and Company, with worldwide sales of approximately $2.6 billion in 1999, is a leading selective serotonin reuptake inhibitor for the treatment of depression
poster:freedom2001
thread:126251
URL: http://www.dr-bob.org/babble/20021101/msgs/126251.html